Day 1

Introductory remarks

Professor Laura JV Piddock, Scientific Director, GARDP

Session 1 – Keynote presentation

Chair: Dr Manica Balasegaram, Executive Director, GARDP

  • Regulatory challenges and global access to new antibiotics
    • Dr Ramanan Laxminarayan, Director, CDDEP

Session 2 – Early drug discovery: new targets and new chemistry

Chair: Dr Adam Roberts, Liverpool School of Tropical Medicine, UK

  • Dual fluorescent timer module for screening of anti-persister agents
    • Professor Ranjana Pathania, Professor Indian Institute of Technology Roorkee (IIT Roorkee)
  • Discovery and optimization of β-sliding clamp (DnaN) inhibitors
    • Professor Dr Anna Hirsch, Head of department, Drug Design and Optimization (DDOP) Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)
  • New ways to identify novel antibacterial chemical entities – Identification of Novel Antibacterials Using Machine Learning Techniques
    • Mr Ed Siegwart, Director of Microbiology, Oppilotech Ltd

Session 3 – Preclinical antimicrobial development

Chair: Dr Taslimarif Sayyed, CEO & Director of C-CAMP

  • WHO Priority pathogen list and WHO preclinical pipeline analysis
    • Dr Valeria Gigante, Team Lead, One Health Research Priority-setting and Synergy in AMR, WHO
  • Overview of CARB-X pipeline
    • Dr Erin Duffy, Chief of Research & Development, CARB-X 

Session 4 – Panel Discussion

Chair: Professor Sujith Chandy, Professor, Department of Pharmacology & Clinical Pharmacology Christian Medical College, Vellore

  • Evidence for the use of old and new antibiotics
    • Dr Susan Hopkins (UKHSA)
    • Dr Priscilla Rupali (Prof Infectious Diseases, Christian Medical College, Vellore)
    • Dr Subasree Srinivasan (Medical Director, GARDP)
    • Prof. Dr Evelina Tacconelli (University of Verona)

Day one closing remark

Dr Christopher Longshaw, Senior Director, EU Scientific Affairs, Shionogi BV & BSAC Honorary Treasurer

Day 2

Introductory remarks

Dr Christopher Longshaw, EU Scientific Advisor, Shionogi & BSAC Honorary Treasurer

Session 5 – Clinical development

Chair: Professor Anil Koul, Vice President and Head of Global Public Health Discovery Research at Johnson & Johnson
and Professor of Translational Discovery at the London School of Hygiene and Tropical Medicine

  • Overview of clinical pipeline for antimicrobials – will it meet the future unmet need?
    • Professor Mical Paul, Head, Division of Infectious Diseases, Rambam Health Care Campus, Israel
  • Emerging antibiotic market in the Indian subcontinent
    • Mr Anmol Aggarwal, Lead, R&D Strategy, Venus Medicine Research Centre, India
  • Clinical development of non-traditional antibiotics
    • Dr Balganesh Tanjore Soundararajan, President, Gangagen Biotechnologies Pvt Ltd, Bangalore, India

Session 6 – Oral Poster Presentations

Chair: Dr Geetanjali Kapoor, Research Fellow, Center for Disease Dynamics, Economics & Policy

  • Evaluating the veterinarian role in one health approach at antimicrobial resistance perspectives, Jordan
    • Bazzi Randa, Faculty of Public Health, University of Debrecen
  • The ESKAPE pathogens mobilome
    • João Botelho, Postdoctoral Researcher, Max Planck Institute for Evolutionary Biology
  • Utilising health belief model to assess antimicrobial awareness of Western Australian parents: A qualitative study
    • Aaron Alejandro, PhD Candidate, Murdoch University Australia
  • Nanobodies as inhibitors of the SOS-response: a new class of potential suppressors of antimicrobial resistance
    • Filippo Vascon, PhD student, Università degli Studi di Padova
  • Phage mediated beta-lactamases and carbapenemases in multi-drug resistant Escherichia coli
    • Juliet Roshini Mohan Raj, Assistant Professor, Nitte University Centre for Science Education and Research

Session 7 – Impact of the COVID-19 pandemic on infections and antimicrobial resistance

Chair: Dr V Ramsubramanian, Consultant Infectious Diseases Apollo Hospitals, Chennai

  • Impact of Covid 19 on Antimicrobial stewardship
    • Dr Andrew Seaton, Consultant in Infectious Diseases and General Medicine, NHS Greater Glasgow and Clyde
  • How has Indian AMR data changed post-Covid
    • Dr Kamini Walia, Program officer AMR Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research
  • Impact of Covid-19 on treatment of fungal infections
    • Dr Arunaloke Chakrabarti, President of International Society for Human and Animal Mycology (ISHAM)

Session 8 – Panel discussion: 

Chair: Professor Philip Howard OBE, AMR Regional Antimicrobial Stewardship Lead NHS England & NHS Improvement – North-East & Yorkshire

  • More than one way to do it – R&D of new antimicrobials: incentives and models
    • Dr Anand Anandkumar, Co-Founder & CEO of Bugworks
    • Dr Jean-Pierre Paccaud, Director, Business Development and Corporate Strategy Global Antibiotic R&D Partnership (GARDP)
    • Ms Jenny Hellmann, Assistant chief of Antibiotics and Infection control unit, Public Health Agency of Sweden

Closing remarks

Professor Laura JV Piddock, Scientific Director, GARDP